License

License Not Specified

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations

To investigate the rate of progression free survival at 6 months in a comparable population of patients with inoperable cholangiocarcinoma treated with either GOC and panitumumab or GOC and bevacizumab

FieldValue
Modified
2019-06-15
Release Date
2019-05-15
Identifier
052ac403-8404-4376-a124-a15128897bbd
License
License Not Specified
Public Access Level
Public